Propranolol Does NOT Cause Peyronie's Disease
Based on FDA drug labeling, propranolol is listed as potentially associated with Peyronie's disease under genitourinary adverse reactions, but this represents an extremely rare reported association rather than an established causal relationship 1. This listing reflects post-marketing surveillance reports, not proven causation.
Key Evidence
FDA Drug Label Information
The FDA label for propranolol lists "Peyronie's disease" under genitourinary adverse reactions alongside male impotence 1. However, this inclusion in the adverse events section does not establish causation—it simply documents that cases have been reported during propranolol use.
Clinical Context
The evidence provided focuses extensively on propranolol's use in infantile hemangiomas, where it is the first-line treatment 2, 3. Multiple comprehensive guidelines from 2015-2019 detail propranolol's adverse effect profile extensively 4, 3, 4:
Well-documented adverse effects include:
- Sleep disturbances (2-18.5% of patients)
- Hypoglycemia (particularly in infants)
- Bradycardia and hypotension (usually asymptomatic)
- Bronchial irritation/bronchospasm
- Cold extremities
- Gastrointestinal symptoms
Notably absent: None of these extensive pediatric or adult guidelines mention Peyronie's disease as a recognized adverse effect, despite detailed documentation of other side effects.
Clinical Interpretation
The association between propranolol and Peyronie's disease appears to be:
- Extremely rare (if it exists at all)
- Not established as causal
- Based on isolated case reports rather than systematic evidence
- Not recognized in major clinical practice guidelines
Practical Recommendation
Do not withhold propranolol therapy based on concern for Peyronie's disease. The documented benefits of propranolol for appropriate indications (infantile hemangiomas, hypertension, cardiac conditions) far outweigh this theoretical and unproven risk. If a patient on propranolol develops Peyronie's disease, consider it coincidental unless temporal relationship strongly suggests otherwise, and evaluate for other known risk factors (trauma, genetic predisposition, connective tissue disorders).
The Peyronie's disease guideline 5 discusses various treatments for the condition but makes no mention of propranolol as a causative agent, further supporting that this is not a recognized clinical association.